Robert Sexe, MD
Surgery · Fulton, MONPI 1124121363
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 22.2% of the total. Reporting peaked in 2019 at $152 and has fallen 75.2% since, to $38 in 2023. That places this record below the midpoint for surgery clinicians in MO, where the typical reported total is $1,517.
Across 19 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$73
- Sunovion Pharmaceuticals Inc.$68
- Otsuka America Pharmaceutical, Inc.$48
- Alkermes, Inc.$47
- AbbVie$43
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$36
- plus $15 from 1 others
What the payments were for
- Food & beverage$331100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 4 | $73 |
| Sunovion Pharmaceuticals Inc. | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Alkermes, Inc. | 3 | $47 |
| AbbVie | 2 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Bioxcel Therapeutics, Inc. | 1 | $15 |
How this compares
$331 in reported general payments places this provider in the 25th percentile of 612 surgery providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $1,149 |
| Levetiracetam | 19 | $450 |
| FenofibrateFenofibrate,micronized | 33 | $422 |
| Levothyroxine Sodium | 105 | $347 |
| Pantoprazole Sodium | 110 | $286 |
| Propranolol Hcl | 23 | $191 |
| Metformin Hcl | 111 | $166 |
| Atorvastatin Calcium | 115 | $162 |
| Desmopressin Acetate | 12 | $145 |
| Oxybutynin Chloride | 15 | $137 |
| Gabapentin | 13 | $94 |
| NyliaNorethindrone-Ethin. Estradiol | 15 | $93 |
| Tamsulosin Hcl | 23 | $67 |
| Famotidine | 33 | $52 |
| Losartan Potassium | 34 | $48 |
Paid to pharmacies, not to this prescriber.
Other surgery in Fulton
- James ScottSaint Louis$307K
- Omar GuerraSaint Louis$249K
- John TannColumbia$216K
- Mark DrakeSaint Louis$212K
- Adeel KhanSaint Louis$204K
- Michael AwadSaint Louis$176K
- Patricia HodginsFenton$145K
- Laurie PunchSaint Louis$141K
- Jeffrey BlatnikSaint Louis$134K
- Bradley MooreKansas City$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.